Home

The THEC laboratory focuses on chemogenomics and the biology of hematologic malignancies, with a strong emphasis on translational research. In collaboration with Hematology at A.O.U. Parma, we integrate small-molecule screening with functional genomics (shRNA/sgRNA, CRISPR/Cas9), cellular biology, and genomic technologies (RNA-seq, ChIP-seq, NGS) to identify novel therapeutic targets. A major focus is the Notch1 pathway, frequently altered in T-ALL, where we recently characterized a novel SERCA inhibitor (CAD204520) with selective anti-leukemic activity and reduced off-target effects. Our team also investigates the role of transcription factors in T-ALL, MCL, and CLL, using chemical libraries and drug profiling platforms to link genomic data with drug sensitivity and uncover new treatment strategies.